| Oct 23 |
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
|
| Oct 18 |
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc
|
| Oct 9 |
Inhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump
|
| Oct 9 |
Inhibikase Therapeutics stock rises after pricing $110M private offering
|
| Oct 9 |
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
|
| Aug 7 |
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
|
| Jun 18 |
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
|
| Jun 17 |
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
|
| May 21 |
Inhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)
|
| May 20 |
Inhibikase Therapeutics prices its direct offering, warrant inducement
|
